Metabolic liver disease might not get as much attention as heart disease or diabetes, but it affects around one in four ...

Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing next-generation peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the ...

Prior to starting the trial, the participants also had moderate to high levels of scar tissue in the liver, known as stage 2 ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Results from the ESSENCE ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

FAT jabs can treat a liver disease affecting one in five people, a trial found. Semaglutide cut inflammation in two thirds of ...

Semaglutide, a drug commonly taken for weight loss, showed marked benefits for most patients in a trial for metabolic dysfunction-associated steatohepatitis (MASH) ...

The diabetes and weight loss drug semaglutide reversed liver scarring and inflammation. It’s among several drugs in the works for the condition MASH.

Semaglutide effectively treats liver disease in two thirds of patients, new research has found.Results from the ESSENCE phase 3 clinical trial ...

The following is a summary of "Metabolic score for visceral fat is correlated with all-cause and cardiovascular mortality ...